Original Research and the Latest News

Not Your Grandparents’ Probability of Success Forecasts

by | November 28, 2024 | New Technology, Probability of Success | 0 Comments

Redefining Probability of Success in Pharma: A Data-Driven Revolution In the world of pharmaceutical strategic planning and analytics, traditional Probability of Success (POS) forecasts are a familiar, yet often frustrating approach to assessing clinical risk. While...

Clinical Trial Success Rates: What Makes Some Companies Stand Out?

by | November 27, 2024 | New Technology, Probability of Success | 0 Comments

Our comprehensive analysis of over 30,000 clinical trials across more than 4,000 biopharmaceutical companies reveals significant variations in clinical trial success rates. This disparity exists even among trials in the same phase and targeting the same disease,...

How Next-Generation Probability of Success Forecasting Can Improve Clinical Trial Accuracy by 44%

by | November 4, 2024 | New Technology, Probability of Success | 0 Comments

Unlocking Next-Gen POS Forecasting for Biopharma Success In the high-stakes world of biopharma, advanced Probability of Success (POS) forecasting can revolutionize the landscape of clinical trials. By adopting next-gen POS forecasting models, companies can...

Recent Posts

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Recent Tweets

Ozmosi Follow

BioPharma/Biotech Intel. Daily $XBI $XPH Market Movers Database: https://t.co/IBOqbSoYuc Clinical trial tools: https://t.co/A77u9Q84Dc https://t.co/AQERg9nHrb

OzmosiHealth
ozmosihealth Ozmosi @ozmosihealth ·
17 Nov

$ALNY Alnylam reports Phase 1 results for Nucresiran, showing consistent TTR reduction for six months after just one dose.

More Info: https://pryzm.ozmosi.com/product/28034 $XBI $IBB $XPH $PPH

Reply on Twitter 1858156159930356191 Retweet on Twitter 1858156159930356191 Like on Twitter 1858156159930356191 1 Twitter 1858156159930356191
ozmosihealth Ozmosi @ozmosihealth ·
17 Nov

Ascentage Pharma's new drug application for Lisaftoclax, a Bcl-2 inhibitor, has been accepted and recommended for priority review by China NMPA's CDE.

More Info: https://pryzm.ozmosi.com/product/19723 $XBI $IBB $XPH $PPH

Reply on Twitter 1858141067436310853 Retweet on Twitter 1858141067436310853 Like on Twitter 1858141067436310853 1 Twitter 1858141067436310853
ozmosihealth Ozmosi @ozmosihealth ·
16 Nov

New analysis from AZALEA-TIMI 71 study shows Abelacimab significantly decreased bleeding in patients on antiplatelet therapy vs. Rivaroxaban Anthos Therapeutics.

More Info: https://pryzm.ozmosi.com/product/19100 $XBI $IBB $XPH $PPH

Reply on Twitter 1857907022391554221 Retweet on Twitter 1857907022391554221 Like on Twitter 1857907022391554221 Twitter 1857907022391554221
ozmosihealth Ozmosi @ozmosihealth ·
16 Nov

AbelZeta reveals preclinical study findings on C-CAR168 for treating autoimmune diseases at ACR Convergence 2024.

More Info: https://pryzm.ozmosi.com/product/33456 $XBI $IBB $XPH $PPH

Reply on Twitter 1857899455540019634 Retweet on Twitter 1857899455540019634 Like on Twitter 1857899455540019634 Twitter 1857899455540019634
Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

Get in Touch

info@ozmosi.com
(732) 701-7807

600 Warren Ave,
Spring Lake, NJ 07762